We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

40 hedge funds and large institutions have $2.32M invested in SAB Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

8% more funds holding

Funds holding: 37 → 40 (+3)

0.05% more ownership

Funds ownership: 0.72% → 0.77% (+0.05%)

48% less capital invested

Capital invested by funds: $4.45M → $2.32M (-$2.13M)

Holders
40
Holders Change
+3
Holders Change %
+8.11%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
10
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FPB
First PREMIER Bank
South Dakota
+$154K
2
IFAM
Institutional & Family Asset Management
Colorado
+$71.1K
3
Mariner
Mariner
Kansas
+$68.5K
4
Citadel Advisors
Citadel Advisors
Florida
+$39.9K
5
Jane Street
Jane Street
New York
+$23.8K

Top Sellers

Rank Fund Capital Flow
1
SOS
Silver Oak Securities
Tennessee
-$64K
2
MC
Meteora Capital
Florida
-$42.7K
3
Millennium Management
Millennium Management
New York
-$25.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$20.5K
5
EMG
ETF Managers Group
New Jersey
-$19K
Name Holding Trade Value Shares
Change 		Change in
Stake
KAS
26
Kestra Advisory Services
Texas
$8K – – –
1SB
27
1ST Source Bank
Indiana
$7K – – –
Fidelity Investments
28
Fidelity Investments
Massachusetts
$6K +$8.93K +900 New
SMG
29
Spectrum Management Group
Indiana
$4K – – –
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$3K +$298 +30 +6%
Osaic Holdings
31
Osaic Holdings
Arizona
$2K – – –
WAM
32
Wolverine Asset Management
Illinois
$2K – – –
JP Morgan Chase
33
JP Morgan Chase
New York
$2K +$814 +82 +45%
Rockefeller Capital Management
34
Rockefeller Capital Management
New York
$1K +$298 +30 +25%
UBS Group
35
UBS Group
Switzerland
$1K +$496 +50 +50%
SOS
36
Silver Oak Securities
Tennessee
– -$64K -5,194 Closed
EMG
37
ETF Managers Group
New Jersey
– -$19K -1,358 Closed
PCM
38
Penserra Capital Management
California
– -$9K -641 Closed
Bank of America
39
Bank of America
North Carolina
– -$308 -31 -40%
Citigroup
40
Citigroup
New York
– -$149 -15 -23%
Wells Fargo
41
Wells Fargo
California
– +$10 +1 +6%
CUAMC
42
China Universal Asset Management Company
China
– +$397 +40 New
1
2

SABS Hedge Fund Activity: Q3 2022 in Review

40 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q3 2022, worth a combined $2.32M — down 48% from $4.45M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new SABS positions and 3 closed out — a net gain of 3 holders — while 10 added to existing stakes and 8 trimmed.

The largest buyer was First PREMIER Bank, adding an estimated $154K. The largest seller was Silver Oak Securities, exiting entirely with an estimated $64K sold.

  • 40 institutional investors held SAB Biotherapeutics (SABS) as of Q3 2022, up from 37 in Q2 2022.
  • Funds reported $2.32M of SAB Biotherapeutics stock for Q3 2022, down 48% quarter-over-quarter.
  • 6 funds opened new SAB Biotherapeutics positions in Q3 2022 and 3 closed out, a net change of +3 holders.
  • The largest SAB Biotherapeutics buyer in Q3 2022 was First PREMIER Bank, an estimated $154K added.
  • The largest SAB Biotherapeutics seller in Q3 2022 was Silver Oak Securities, an estimated $64K sold.

Based on aggregated 13F filings for Q3 2022.